Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etiological agent of the coronavirus disease 2019 (COVID-19), has led to more than 425 million cases and more than 5.9 million deaths globally (WHO, 2021). Since the World Health Organization (WHO) declared the outbreak of COVID-19 as...

• Auteur principal: López Cortés, Andrés (author)
• Autres auteurs: Guerrero, Santiago (author), Ortiz Prado, Esteban (author), Yumiceba, Verónica (author), Vera Guapi, Antonella (author), León Cáceres, Ángela (author), Simbaña Rivera, Katherine (author), Gómez Jaramillo, Ana María (author), Echeverría Garcés, Gabriela (author), García Cárdenas, Jennyfer M. (author), Puig San Andrés, Lourdes (author), Guevara Ramírez, Patricia (author), Cabrera Andrade, Alejandro (author), Bautista, Jhommara (author), Pérez Villa, Andy (author), Ramos Medin, María José (author), Pérez Meza, Álvaro Alexander (author), Nieto Jaramillo, Karol (author), Jácome, Andrea V. (author), Morillo, Andrea (author)
• Format: article
• Publié: 2022
• Sujets: ulmonary inflammatory response; Clinical trials, drugs; Lethal COVID-19; Single nucleus RNA sequencing
• Accès en ligne: https://doi.org/10.3389/fphar.2022.833174; http://repositorio.ikiam.edu.ec/jspui/handle/RD_IKIAM/529